Public domain

Strings Sensation Violectric Present Free Online Music Education And Entertainment Series Starting This Thursday, June 4

Retrieved on: 
Monday, June 1, 2020
Intellectual property law, Digital art, Free content, Copyright, Music lesson, Public domain, Contents, Articles, Mass media

In an effort to provide education and entertainment for students of all ages, Founder of the captivating Central Florida based strings band Violectric and renowned "Vinylinist" Michelle Jones has created the Violectric Education Program SPARKS video series.

Key Points: 
  • In an effort to provide education and entertainment for students of all ages, Founder of the captivating Central Florida based strings band Violectric and renowned "Vinylinist" Michelle Jones has created the Violectric Education Program SPARKS video series.
  • Available starting this Thursday, June 4 with an all-new video released each week, the fun and free online series will feature different musicians and facilitators from Violectric and Violectric's philanthropy, Violectric Education Programs, presenting short educational lessons with a mini concert concluding each video.
  • They are designed to be a mix of 'How It's Made' meets mini concert as seen on reality TV shows.
  • All videos are free on several platforms for viewing, and they contain only original, public domain or copyright-obtained music.

Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 26, 2020
Pharmaceutical industry, Articles, Life sciences, Generic drug, Pharmaceuticals policy, Public domain, Pharmaceutical industry in India, Industries

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Retrieved on: 
Saturday, May 23, 2020
Articles, Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacy, Generic drug, Public domain, Medication, Antiviral drug

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.

Key Points: 
  • However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.
  • The report provides a comprehensive analysis of the global antiviral drugs market.

Insights into the Worldwide Antiviral Drugs Industry to 2024 - Potential Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 22, 2020
Infectious diseases, Pharmaceutical, Health, Articles, Health, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Antiviral drug, Medication

The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.

Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Retrieved on: 
Wednesday, May 13, 2020
Pharmaceutical industry, Articles, Life sciences, Generic drug, Pharmaceuticals policy, Public domain, Pharmaceutical industry in India, Industries

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020

Retrieved on: 
Friday, May 8, 2020
Pharmaceuticals policy, Articles, Health, Life sciences, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in India, Pharmaceutical industry in China

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Amneal Launches Generic Butrans® Following ANDA Approval by FDA

Retrieved on: 
Thursday, April 16, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Drugs, Opioids, Health, RTT, Pharmaceutical industry, Euphoriants, Generic drug, Pharmaceuticals policy, Public domain, Amneal Pharmaceuticals, Buprenorphine, Abbreviated New Drug Application

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr.
  • In addition, Amneal was granted the Competitive Generic Therapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose.
  • Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
  • Amneal Co-Chief Executive Officers Chirag Patel and Chintu Patel said, Expanding our portfolio of complex generic drug products and providing patients access to affordable generic medicines will continue to set Amneal apart.

FPP and Inventia Sign Licensing and Supply Agreement

Retrieved on: 
Friday, April 3, 2020
Health, Pharmaceuticals policy, Articles, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in China, Food and Drug Administration, Pharmaceutical industry in India

(FPP), a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals, and Inventia Healthcare Limited (Inventia), a company involved in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of an ANDA developed by Inventia recently approved by the FDA and scheduled to launch this Summer.

Key Points: 
  • (FPP), a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals, and Inventia Healthcare Limited (Inventia), a company involved in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of an ANDA developed by Inventia recently approved by the FDA and scheduled to launch this Summer.
  • The ANDA product will be Sold and Distributed by FPP in the FPP Label within the US.
  • "We are excited to work with Inventia on this opportunity and look forward to launching the product ", said Larry J. Lapila, President of FPP.
  • "Inventia is excited to add a new partner to the current portfolio of ANDAs and we are working together with FPP towards a successful launch of the product", said Ankur J. Shah, Whole-time Director of Inventia.

Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026

Retrieved on: 
Wednesday, April 1, 2020
Articles, Health, Life sciences, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry

NEW YORK, April 1, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

Key Points: 
  • NEW YORK, April 1, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    Since the arrival of the generic drugs approach 30 years ago, the market is showing a tremendous elevation in the consumption rate of the cancer generics across the globe: the reasons being the uncontrollably growing population and the unmanageable crisis of cancer mortality.
  • The ease in developing the drug and the high adoption rate by the patients contribute largely to the established markets of cancer generics.
  • Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive.
  • The research report "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" provides an in-depth analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governing and regulatory bodies around the globe.

Global Generic Drugs Market Analysis to 2026 - Vendors Covered Include Cipla, Novartis, Valeant & Baxter International Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 27, 2020
Health, Pharmaceutical, Pharmaceuticals policy, Articles, Health, Pharmaceutical industry, Life sciences, Generic drug, Public domain, Drug, Abbreviated New Drug Application, Food and Drug Administration

The "Global Generic Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Generic Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Generic Drugs market is expected to reach $738.56 billion by 2026 growing at a CAGR of 12.6% from 2018 to 2026.
  • Generic drugs are drugs with the chemical makeup of a drug equivalent to an existing branded drug.
  • These drugs are cheaper and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application.